Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.
- DOI
- 10.1016/j.ymthe.2026.04.018
- Published
- 2026 May 6
- Container
- Molecular therapy : the journal of the American Society of Gene Therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ymthe.2026.04.018,
title = {Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.},
author = {Do Cao J and Gao-Desliens J and Valent A and Knuchel-Legendre N and Colpin C and Guyon H and Winstedt L and Leborgne C and Perret G and Ronzitti G and Labrune P},
year = {2026},
journal = {Molecular therapy : the journal of the American Society of Gene Therapy},
doi = {10.1016/j.ymthe.2026.04.018},
url = {https://doi.org/10.1016/j.ymthe.2026.04.018}
}RIS
TY - JOUR TI - Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift. AU - Do Cao J AU - Gao-Desliens J AU - Valent A AU - Knuchel-Legendre N AU - Colpin C AU - Guyon H AU - Winstedt L AU - Leborgne C AU - Perret G AU - Ronzitti G AU - Labrune P PY - 2026 JO - Molecular therapy : the journal of the American Society of Gene Therapy DO - 10.1016/j.ymthe.2026.04.018 UR - https://doi.org/10.1016/j.ymthe.2026.04.018 ER -
APA
J, D. C., J, G., A, V., N, K., C, C., H, G., L, W., C, L., G, P., G, R., & P, L. (2026). Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.. Molecular therapy : the journal of the American Society of Gene Therapy. https://doi.org/10.1016/j.ymthe.2026.04.018
Source records
- pubmed · retrieved 2026-09-25T23:02:03.695Z